Managing metastatic gastric cancer

Share :
Published: 20 Dec 2016
Views: 1708
Rating:
Save
Prof Daisuke Sakai - Osaka University, Osaka, Japan

Prof Sakai speaks with ecancertv at the Immuno-Oncology Hong Kong 2016 meeting about the staging of therapies for metastatic gastric cancer.

He outlines which therapy is suited to first and second line therapy, with ongoing research for immunotherapy and targeted molecules work in combination for these patients.

In Japan we treat with chemotherapy for the patients with metastatic gastric cancer.

What drugs do you typically use as treatment?

S-1 or capecitabine plus platinum, cisplatin or oxaliplatin; for the patients with HER2 positive gastric cancer trastuzumab will be added to this combination. Second line ramucirumab plus paclitaxel is usually used.

What clinical trials and drugs are you currently interested in?

For me, now we focus on the immune checkpoint agents like nivolumab or pembrolizumab.

Are you researching MET?

Yes, but it’s difficult so successful data we don’t have.

What angiogenesis drugs are showing potential?

It’s a very good drug so we use ramuciriumab in clinical practice. Ramuciriumab is a very effective drug, I think.